Article Figures & Data
Figures
- Figure 1.
Anticipated changes in physician practice following ACIP recommendation for SCDM regarding HPV vaccination of adults 27 to 45 years, United States, 2019 to 2020 (n = 534). Abbreviations: ACIP, Advisory Committee on Immunization Practices; SCDM, shared clinical decision making; HPV, Human Papillomavirus.
Tables
- Table 1.
Demographic and Practice Characteristics of Survey Respondents and Non-Respondents, United States, 2019-2020 (n = 968)
Characteristic Respondents (n = 617) Non-Respondents (n = 351) P-Value Mean (SD) physician age, years 54.8 (9.4) 56.7 (9.1) .002*† Female, % 50 38 < .001* Specialty, % Family physician 54 39 < .001* General internist 46 61 Region of the United States, % Midwest 24 26 .08 Northeast 19 21 South 33 36 West 24 17 Location of practice, % Urban 27 23 .19 Suburban 67 68 Rural 6 9 Practice setting, %‡ Private practice 66 78 < .001* Hospital or clinic 25 17 Health maintenance organization 9 5 Median (IQR) number of providers in practice 6 (3 to 12) 5 (2 to 10) .002*§ Decisions are made about purchasing and handling vaccines, % Independently 53 57 .28 At a larger system level 47 43 - Table 2.
Physician Knowledge of HPV Disease and HPV Vaccination, United States, 2019 to 2020 (n = 617)
Knowledge Concept: True or False? Correct Answer Physicians Answering Correctly (%) Physicians Answering Incorrectly (%) Physicians Answering, “Don’t Know” (%) Adults who have a new sex partner are at risk of acquiring a new HPV infection True 96 1 3 ACIP recommends against 9vHPV in unvaccinated adults age 27 through 45 years who have had multiple sex partners False 70 11 19 People who started the HPV vaccination series with an older vaccine can complete the series with 9vHPV* True 65 6 30 HPV antibody testing is recommended for adults age 27 through 45 years as a part of shared clinical decision making for HPV vaccination False 64 13 23 Full HPV vaccination of an adult who started the series as an adult will require three doses of 9vHPV* True 56 21 24 ACIP recommends against 9vHPV in unvaccinated adults age 27 through 45 years who have had a diagnosed HPV infection False 55 10 35 HPV vaccine prevents progression of existing HPV related cancers False 45 17 38 HPV vaccine prevents progression of existing HPV infection False 38 22 41 HPV vaccine effectiveness is lower for adults age 27 through 45 years compared to adults age 18 through 26 years True 30 30 41 Studies show that HPV vaccine is very effective in adults age 27 through 45 years with HIV infection False 8 37 56 Some percentages do not add up to 100% because of rounding.
↵* P ≤ .05 for statistical differences between specialties. Seventy-one percent of FP and 57% of GIM answered correctly that when HPV vaccination series was started with an older vaccine, it can be completed with 9vHPV. Fifty-nine percent of FP and 51% of GIM were aware that when HPV vaccination started as an adult requires 3 doses.
HPV, Human Papillomavirus; ACIP, Advisory Committee on Immunization Practices; HIV, human immunodeficiency virus.
